Night-time exogenous melatonin administration may be a beneficial treatment for sleeping disorders in beta blocker patients

Abstract

Sleep disorders are the common side effects of beta blockers. Beta blockers have been shown to reduce the 
production of melatonin via specific inhibition of adrenergic beta1-receptors. Exogenous melatonin, taken 
in the evening as a supplement, could reduce the central nervous system (CNS) side effects (sleep disorder) 
associated with beta-adrenergic receptor blockers as well as the potential risk associated with reduction of the 
melatonin synthesis